ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Obituary: Selma Schimmel, Founder of Vital Options, Dies of Cancer

May 23, 2014

Early HER2 Positive Patients At Higher Risk of Recurrence

January 30, 2009

NIH announces The Cancer Genome Atlas, new name for human cancer genome project.

December 16, 2005

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

March 25, 2011

Clearinghouse Delves Into Carcinogenesis Issues – Test Validity, Interpretation, In Vitro Methods

August 12, 1977

Phase III Trial of ThermoDox Fails to Meet Primary Endpoint

February 22, 2013